Compare Natco Pharma with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs UNICHEM LAB - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA UNICHEM LAB NATCO PHARMA/
UNICHEM LAB
 
P/E (TTM) x 15.6 63.4 24.5% View Chart
P/BV x 3.1 0.7 448.3% View Chart
Dividend Yield % 1.5 2.0 71.8%  

Financials

 NATCO PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
UNICHEM LAB
Mar-19
NATCO PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs1,080292 369.9%   
Low Rs671182 368.8%   
Sales per share (Unadj.) Rs592.1167.7 353.1%  
Earnings per share (Unadj.) Rs188.4-3.6 -5,189.1%  
Cash flow per share (Unadj.) Rs206.35.9 3,472.8%  
Dividends per share (Unadj.) Rs8.254.00 206.3%  
Dividend yield (eoy) %0.91.7 55.8%  
Book value per share (Unadj.) Rs833.6372.3 223.9%  
Shares outstanding (eoy) m36.9070.38 52.4%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x1.51.4 104.6%   
Avg P/E ratio x4.6-65.3 -7.1%  
P/CF ratio (eoy) x4.239.9 10.6%  
Price / Book Value ratio x1.10.6 165.0%  
Dividend payout %4.4-110.2 -4.0%   
Avg Mkt Cap Rs m32,31116,680 193.7%   
No. of employees `0004.82.6 185.7%   
Total wages/salary Rs m3,2562,393 136.1%   
Avg. sales/employee Rs Th4,522.54,535.2 99.7%   
Avg. wages/employee Rs Th674.0919.8 73.3%   
Avg. net profit/employee Rs Th1,439.0-98.2 -1,465.3%   
INCOME DATA
Net Sales Rs m21,84811,801 185.1%  
Other income Rs m404984 41.1%   
Total revenues Rs m22,25212,785 174.1%   
Gross profit Rs m9,284-835 -1,112.0%  
Depreciation Rs m662674 98.3%   
Interest Rs m15475 204.8%   
Profit before tax Rs m8,872-600 -1,479.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,920-343 -559.0%   
Profit after tax Rs m6,952-256 -2,720.6%  
Gross profit margin %42.5-7.1 -600.6%  
Effective tax rate %21.657.3 37.8%   
Net profit margin %31.8-2.2 -1,469.5%  
BALANCE SHEET DATA
Current assets Rs m21,30720,384 104.5%   
Current liabilities Rs m5,9205,029 117.7%   
Net working cap to sales %70.4130.1 54.1%  
Current ratio x3.64.1 88.8%  
Inventory Days Days73105 69.9%  
Debtors Days Days107135 79.0%  
Net fixed assets Rs m14,9869,023 166.1%   
Share capital Rs m369141 262.1%   
"Free" reserves Rs m30,35326,058 116.5%   
Net worth Rs m30,76026,199 117.4%   
Long term debt Rs m00-   
Total assets Rs m37,15131,496 118.0%  
Interest coverage x58.6-7.0 -840.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.60.4 157.0%   
Return on assets %19.1-0.6 -3,340.7%  
Return on equity %22.6-1.0 -2,317.2%  
Return on capital %29.3-2.0 -1,467.7%  
Exports to sales %069.4 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA8,188 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,3228,188 126.1%   
Fx outflow Rs m2,978596 499.7%   
Net fx Rs m7,3437,592 96.7%   
CASH FLOW
From Operations Rs m4,636-3,278 -141.4%  
From Investments Rs m-11,155-2,860 390.0%  
From Financial Activity Rs m6,509-24 -26,896.7%  
Net Cashflow Rs m-18-4,690 0.4%  

Share Holding

Indian Promoters % 52.0 50.1 103.9%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 15.1 51.9%  
FIIs % 16.6 3.0 554.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 31.7 82.0%  
Shareholders   25,395 20,176 125.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   DR. REDDYS LAB  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare NATCO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms Over 1,900 Points after Government Slashes Corporate Tax Rates(12:30 pm)

Share markets in India jumped sharply after FM Nirmala Sitharaman announced a slew of measures in her media briefing ahead of the GST Council meet.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 20, 2019 03:21 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - FULFORD INDIA COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS